Stockreport

New England Journal of Medicine Publishes Results from Pivotal Phase 3 Studies of Paratek’s NUZYRA™ (Omadacycline) For Pneumonia and Skin Infections

Paratek Pharmaceuticals, Inc.  (PRTK) 
Last paratek pharmaceuticals, inc. earnings: 2/25 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.paratekpharma.com
PDF BOSTON, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a biopharmaceutical company focused on the development and commercialization of [Read more]